BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

SoluLinK, Inc. Announces IRS Federal Grant Award to Advance its New Multiplexing and Detection Technology for Research and Diagnostics Applications Used for Accelerating Therapeutics Development


9/15/2011 12:06:53 PM

San Diego, California—November 15, 2010. Solulink, Inc., a leading innovator of state-of- the-art conjugation reagents, easy-to-use linking kits, and conjugation services for the life science research, diagnostics, and pharmaceutical markets, today announced it has been awarded a $194,500 grant under the Qualifying Therapeutic Discovery Project program established under Section 48D of the Internal Revenue Code. The grant will aid the company in advancing its new multiplexing detection platform (HybriLink™) for assay development that could potentially be used in a variety of assays including cancer diagnostics and assays used in the development of new therapeutics. Applications include immunohistochemistry, flow cytometry, and many others all which will work on existing laboratory instrumentation. Using Solulink’s new HybriLink™ platform, researchers can potentially develop more informative and accurate diagnostics, accelerate the discovery and development and of more effective therapeutics, and consequently reduce the costs associated with research, development, and patient care.

The Qualifying Therapeutic Discovery Project is targeted at therapeutic discovery projects that show a reasonable potential to:

- Result in new therapies to treat areas of unmet medical need or prevent, detect, or treat chronic or acute diseases and conditions,

- Reduce the long-term growth of health care costs in the United States, or

- Significantly advance the goal of curing cancer within 30 years.

About Solulink

Solulink’s proprietary conjugation reagents and easy-to-use linking kits provide unique features and benefits used to link proteins, oligonucleotides, peptides, and antibodies to each other or to a wide range of surfaces including beads, chips, and slides. Solulink markets its products both directly and through distributors and licensing partners worldwide. Solulink is a privately held company located in San Diego, California. For more information, please visit www.solulink.com.

Contact

Steve DeGraw

Solulink, Incorporated

9853 Pacific Heights Blvd. Suite H

San Diego, California 92121

T 858.625.0670

F 858.625.0770

sdegrawsolulink.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES